Webinar ICEX- “Spain as a strategic investment destination for mexican companies in the health sector"
The registration deadline is May 19 at 5:00 p.m.
The Economic and Commercial Office of Spain in Mexico and ICEX–Invest in Spain are organizing the videoconference “Spain as a strategic investment destination for mexican companies in the health sector”.
This free webinar, to be held on May 20, 2026, at 8:00 a.m. (Mexico time), will analyze the fundamental role of the health sector as one of the strategic pillars of the Spanish economy. During the session, we will explore the high added value it contributes to Spain’s business ecosystem—ranking among the top ten sectors with the largest stock of foreign direct investment—and provide key information on the regulatory environment, business opportunities, and growth prospects that Spain offers to international investors. The Spanish ecosystem stands out for its strong appeal to foreign companies, thanks to its leading scientific output—ranking as the 9th largest globally and 3rd in Europe.
This strength, combined with a highly skilled workforce, state-of-the-art infrastructure, and an integrated healthcare system, enables the development of innovative products across the entire value chain, from the early stages of research through development, validation, and production.
The health sector in Spain has consolidated its position as one of the most dynamic and competitive worldwide, supported by a solid business fabric that includes nearly 1,000 biotechnology companies, 500 pharmaceutical firms, and 1,000 medical technology companies.
This industrial strength, backed by a network of 850 hospitals and research centers, has positioned the country as the European leader and the world’s third-largest hub for clinical trials, with annual investment exceeding €900 million. As a result, the combination of a mixed hospital infrastructure (public and private) and an advanced regulatory framework provides international companies with the ideal environment for the clinical validation of their products. *This activity is not related to FEDER or PRTR funding*